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Abstract
Visceral leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani, L. chagasi and L. infantum is
characterized by defective cell-mediated immunity (CMI) and is usually fatal if not treated properly. An estimated 350 million
people worldwide are at risk of acquiring infection with Leishmania parasites with approximately 500,000 cases of VL being
reported each year. In the absence of an efficient and cost-effective antileishmanial drug, development of an appropriate
long-lasting vaccine against VL is the need of the day. In VL, the development of a CMI, capable of mounting Th1-type of
immune responses, play an important role as it correlate with recovery from and resistance to disease. Resolution of
infection results in lifelong immunity against the disease which indicates towards the feasibility of a vaccine against the
disease. Most of the vaccination studies in Leishmaniasis have been focused on promastigote- an infective stage of parasite
with less exploration of pathogenic amastigote form, due to the cumbersome process of its purified isolation. In the present
study, we have isolated and purified splenic amastigotes of L. donovani, following the traditional protocol with slight
modification. These were fractionated into five membranous and soluble subfractions each i.e MAF1-5 and SAF1-5 and were
subjected for evaluation of their ability to induce cellular responses. Out of five sub-fractions from each of membrane and
soluble, only four viz. MAF2, MAF3, SAF2 and SAF3 were observed to stimulate remarkable lymphoproliferative, IFN-c, IL-12
responses and Nitric Oxide production, in Leishmania-infected cured/exposed patients and hamsters. Results suggest the
presence of Th-1 type immunostimulatory molecules in these sub-fractions which may further be exploited for developing a
successful subunit vaccine from the less explored pathogenic stage against VL.
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Introduction
Visceral leishmaniasis (VL) is the most fatal among the
complex of leishmaniases and is caused by the invasion of the
reticuloendothelial system by the hemoflagellate protozoan
parasite, Leishmania donovani, Leishmania infantum, and Leishmania
chagasi. VL is endemic in 62 countries, with a total of 200 million
people at risk and an estimated 500 000 new cases arising each
year worldwide [1]. Toxicity of currently available drugs
alongwith limited efficacy and emerging resistance to these
antileishmanials is an encumbrance for ongoing available
treatment regimens and is of significant concern [2]. It is well
known that during active VL there is profound immunosuppres-
sion and development of an effective CMI, capable of mounting
Th1-type of immune response, plays an important role in
controlling Leishmania infections in experimental and human VL
[3,4]. Thus, in the abovesaid scenario, development of an
effective vaccine against leishmaniasis should be a priority of
tropical disease research.
Further, in areas endemic for visceral leishmaniasis, there
appears to be a significant population of individuals who have had
in-apparent or self-resolving infection with L. donovani and are
presumably resistant to visceral disease. This may provide a
rationale for designing immunoprophylactic strategies against VL.
Unfortunately, the development of vaccines has been hampered by
significant antigenic diversity along with the fact that the parasites
have a digenetic life cycle in at least two hosts- vector and human,
there are differences in the host cell responses following interaction
with either promastigote or amastigote forms or their antigens
[5,6]. Since the promastigote form can be readily cultivated in cell-
free media at room temperature (23 to 27uC), the majority of
studies have investigated the host cell response initiated by
Leishmania promastigotes [7,8]. Our earlier studies have also aimed
at identifying promastigote antigens (membranous as well as
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soluble) from a field isolate of Leishmania spp. for the molecules
having ability to stimulate Th1-type response, which is known to
be the major defense mechanism against Leishmania infection
[3,4,9,10,11]. It has been reported that some T-cell epitopes that
are protective in the murine host do not elicit an immune response
in human [12], emphasizing the importance of evaluating
leishmanial antigens for their cellular immune responses in
patients’ samples. Keeping this view, we made an attempt to
translate and compare the observations in hamster model, a
perfect model mimicking progressive human VL, with patients’
samples. Both the membranous as well as soluble antigens induced
significant proliferative responses and IFN-c production in
lymphocytes isolated from cured VL patients and cured hamsters
[13]. Encouraged with the results we further fractionated
promastigote soluble lysate into 5 fractions and assessed these for
their immunogenicity as well as immunoprophylactic efficacy. Out
of these, fraction # 2 (F2) ranging from 68–97.4 kDa elicited
considerably good T cell responses in individuals who had
recovered from VL and endemic contacts as well as in cured
hamsters [13,14]. In addition, F2 fraction showed considerably
good prophylactic activity together with BCG against L. donovani
challenge [13]. Thus, generation of similar type of responses in
both the hosts against leishmanial antigens encouraged the fact
that findings obtained with hamster model can be translated
clinically in future.
Abovesaid observations with promastigotes led to the necessity
and importance to dissect the membrane and soluble proteins of
amastigote form, which is actually responsible for disease
pathogenesis, and thus can be a more potential yet unexplored
reservoir of immunostimulatory antigens. The reason behind less
exploration of splenic amastigotes for vaccine development is the
time-consuming and low yielding isolation of this stage, either
from lesions or by in vitro cultivation in macrophages and
macrophage-like cell lines, alongwith the major issue of contam-
ination of host components. However, the availability of axenic
cultures of several Leishmania strains [15,16,17] has allowed
detailed studies of biological and immunologic functions of
amastigote proteins. But these axenic forms can be grown only
for the few Leishmania species- particularly of cutaneous forms,
and although they display a number of biochemical markers of the
intracellular stage [18], they fail to synthesize some major products
of true amastigotes, e.g. the secreted amastigote-specific proteopho-
sphoglycans in the case of Leishmania mexicana. Moreover, recent
genome-wide mRNA profiling suggests that axenic amastigotes are
more closely related to promastigotes than to ex-vivo isolated
amastigotes [19] emphasizing the need to shift the studies with
‘true’ amastigotes to get into its authentic data.
The present study was conducted with the same line of work, as
was performed with promastigote, in splenic intracellular amastigote
stage. Herein, we fractionated membrane as well as soluble fractions
of amastigotes into five sub-fractions according to their molecular
weights and evaluated these for their ability to stimulate cellular
responses in the macrophages and lymphocytes of Leishmania infected
and cured patients as well as hamsters to identify and ascertain the
specific immunostimulatory fractions or constituents in them.
Results
L. donovani amastigotes isolated from infected spleen
were free of host contaminants
Since host contamination is the major issue with all the studies
related to splenic amastigotes it was essential to ensure the removal
of host debris from the amastigote suspension, isolated from
infected spleen. This was done by confocal microscopy using
antibody against proteophosphoglycan which we have used for the
same purpose earlier also [29]. Amastigotes showed bright green
fluorescence throughout their outer surface and flagellar pocket
(Fig. 1.). The control antibodies (normal rabbit serum) used
showed no fluorescence. As observed in DIC as well as fluorescent
images, there was no host contaminants observed in amastigotes
purified by this protocol.
Isolation and SDS-PAGE analysis of sub-fractions
The purified amastigote suspension was fractionated into MA
and SA and further sub-fractionated into five sub-fractions to
homogeneity by electro-elutor (Fig. 2 A). Total 5 sub-fractions
were collected for MA and SA each (Fig. 2 B, C). The purity and
accuracy of the samples was assessed by SDS-PAGE, followed by
silver staining. Five discrete sub-fractions for MA and SA were
MAF1, MAF2, MAF3, MAF4, MAF5 (MW ranges of 205-97, 97-
68, 68-43, 43-29, 29-10 respectively) and SAF1, SAF2, SAF3,
SAF4, SAF5 (MW ranges of 205-97, 97-68, 68-43, 43-29, 29-10
respectively).
Verification of amastigotes proteins through expression
of LPG and A2 by Western blot
Further, to ensure that the proteins we have used in the study
are derived from amastigotes, we took promastigote as well as
amastigote specific marker antibodies against LPG as well as A2
respectively. LPG of promastigotes is antigenically and biochem-
ically different from amastigotes [30]. Similarly, A2 protein is a
stage specific protein of amastigotes [31]. Immunoblot analysis of
whole cell lysate of splenic amastigotes and promastigotes with
monoclonal antibody against promastigotes LPG revealed the
presence of LPG in promastigotes but its absence in amastigotes
(Fig. 2E).The loading control indicated a similar abundance of the
endoplasmic reticulum protein grp78 in both the stages of
parasites(Fig. 2D). Similarly, immunoblot analysis using monoclo-
nal antibody against amastigotes A2 revealed its presence in
amastigotes only (Fig. 3).
Evaluation of Th1 stimulatory cellular responses of
potential fractions with PBMCs of cured/endemic
Leishmania patients
Lymphoproliferative response. Since, in Indian kala-azar
as well as in experimental models it was reported that impairment
of cell-mediated immune response is reflected by marked T cell
anergy specific to Leishmania antigens [40,41,42], we assessed the
Figure 1. Immunolocalization of PPG in pure amastigotes
derived from splenic tissue by confocal laser scanning
microscopy. (a) DIC image (Differential interference contrast image)
of purified amastigotes in confocal microscopy which is similar to that
obtained by phase contrast microscopy but without the bright
diffraction halo (b) Fluorescent image of purified amastigotes using
anti-PPG antibody with secondary anti-rabbit FITC labeled IgG.
doi:10.1371/journal.pone.0030746.g001
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Figure 2. Silver stained 12% SDS-PAGE gels showing soluble antigenic fraction/SA & membrane antigenic fraction/MA (A) as well
as purified sub-fractions of MA (B) and SA (C) according to their molecular weight. Western blot analysis of amastigotes and
promastigotes using (i) GRP-78 antibody as loading control (D), (ii) mouse monoclonal LPG against promastigotes (E). Lane 1: Amastigote lysate; Lane
2: promastigote lysate.
doi:10.1371/journal.pone.0030746.g002
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cellular responses in PBMCs of cured patients, endemic and non
endemic healthy controls and L. donovani infected donors at a
predetermined optimum concentration of 10 mg/ml. Individual
donors were found to elicit different responses as compared to
endemic control and cured patients. Endemic control and cured
patients exhibited relatively higher SI index to the tune of
53.1866.68 and 45.0765.029 respectively against PHA as
compared to unstimulated control (data not shown). The
response to membrane sub-fractions MAF2 and MAF3 was
nearly same and positive in 8 out of 10 cured Leishmania patients
(mean SI value 19.57 with range of 2.7–30.80 for MAF2 and mean
SI value 22.05 with range of 12.70–31.20 for MAF3) and in 8 out
of 9 endemic controls (mean SI value 13.75 with range of 2.73–
30.80 for MAF2; P,0.001 and mean SI value 11.76 with range of
1.03–21.30 for MAF3). Among the various soluble antigenic sub-
fractions, SAF2 showed optimum proliferative response in cured
(mean SI value 19.32 with range of 1.28–29.23; P,0.001) as well
as endemic contacts (mean 13.54 with range of 8.2–17.9) (Fig. 4.)
followed by SAF3 in soluble sub-fractions. Among the individual
soluble sub-fractions SI values in cured/endemic for respective
sub-fractions SAF1, SAF4, and SAF5 showed to be very poor
response. Similar responses were observed with other three
membrane sub-fractions.
There was no mitogenic as well as antigenic (all the individual
sub-fractions as well as pooled one) proliferative response in
Leishmania infected patients (data not shown).
Estimation of cytokine (IFN-c, IL-12p40 and IL-10) levels
The absence of a type 1 immune response to Leishmania antigen is
documented in patients with VL along with activation of Th2-type
Figure 3. Western blots analysis of amastigotes and promas-
tigotes using mouse monoclonal A2 antibody against amasti-
gotes. Lane 1: promastigote lysate; Lane 2: Amastigote lysate.
doi:10.1371/journal.pone.0030746.g003
Figure 4. Lymphoproliferative response of PBMCs from Cured VL patients (&), Endemic controls (m) and healthy (o) individuals
against membrane antigenic fractions/MA and soluble antigenic fractions/SA.
doi:10.1371/journal.pone.0030746.g004
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cytokines resulting in progressive disease whereas Th1- type cytokine
responses have been reported to play a critical role in protection
against infection with Leishmania parasites (cured patients). Keeping
this in view, the level of Th1 stimulatory i.e. IFN-c & IL-12p40 as
well as Th2 stimulatory IL-10 was estimated in PBMCs from cured
patients as well as in endemic contacts against all the membrane and
soluble subfractions. Optimum stimulation of IFN-c and IL-12p40
responses was again noticed against subfraction MAF2, MAF3,
SAF2 in 8 cured patients and 8 out of 9 endemic contacts followed
by SAF3. The level of IFN-c in cured patients stimulated by
subfractions MAF2 and MAF3 was nearly same and positive in 8 out
of 10 cured (593 pg/ml with range of 209–785 pg/ml for MAF2
and 510 pg/ml with range of 239–709 pg/ml for MAF3). Similarly,
in endemic contacts IFN-c level was 401 pg/ml with range of 236–
645 pg/ml for MAF2 and 319 pg/ml with range of 189–574 pg/ml
for MAF3. The level of IL-12p40 in cured patients stimulated by
subfractions MAF2 and MAF3 was also nearly the same and positive
in 8 out of 10 cured (530 pg/ml with range of 330–665 pg/ml for
MAF2 and 628 pg/ml with range of 483–754 pg/ml for MAF3).
Similarly, in endemic contacts IL-12p40 level were 449.7 pg/ml
with range of 245–546 pg/ml for MAF2 and 506 pg/ml with range
of 324–674 pg/ml for MAF3. The level of these cytokines was
comparatively lower against the individual subfractions in the above
stated study groups. Moreover, no detectable amount of IFN-c and
IL-12p40 level was observed with the lymphocytes of the six L.
donovani infected patients (data not shown) and 7 healthy individuals
with other antigenic sub-fractions.
The level of IFN-c in cured patients stimulated by subfractions
SAF2 was positive in 9 out of 10 cured patients followed by
SAF3in which it was not very significant (534 pg/ml with range of
133–856 pg/ml for SAF2 and 180 pg/ml with range of 111–
285 pg/ml for SAF3). Similarly, in endemic contacts IFN-c level
was 376 pg/ml with range of 121–621 pg/ml for SAF2. The level
of IL-12p40 in cured patients stimulated by subfractions SAF2 and
SAF3 was positive in all the cured patients(688.8 pg/ml with
range of 507.2–879.7 pg/ml for SAF2 and 265 pg/ml with range
of 163.6–349 pg/ml for SAF3). Similarly, in endemic contacts IL-
12p40 level was 614 pg/ml with range of 430–868 pg/ml for
SAF2. The level of these cytokines was comparatively lower
against the individual subfractions in the above stated study
groups. Moreover, no detectable amount of IFN-c and IL-12p40
level was observed with the lymphocytes of the six L. donovani
infected patients (data not shown) and 7 healthy individuals with
other antigenic subfractions.(Fig. 5.)
On the other hand low level of IL-10 cytokine against MAF2,
MAF3, was found in cured patients (13.89 pg/ml with range of
4.02–44.03 pg/ml for MAF2 and 12.41 pg/ml with range of 5.32–
28.93 pg/ml for MAF3) as well as in endemic contacts (12.77 pg/
ml with range of 5.89–23.07 pg/ml for MAF2 and 16.93 pg/ml
with range of 5.38–44.71 pg/ml for MAF3) was noticed (Fig. 6.).
Level of IL-10 was also found very low in SAF2 and SAF3
subfractions in cured patients (9.76 pg/ml with range of 5.5–29 pg/
ml for SAF2 and 7.80 pg/ml with range of 1.11–16.80 pg/ml for
SAF3).In endemic controls also IL-10 was found in very low levels
(8.92 pg/ml with range of 3.8–26.53 pg/ml for SAF2 and 7.24 pg/
ml with range of 1.03–17.20 pg/ml for SAF3). But in all six infected
patients IL-10 cytokine level was increased (data not shown) as
compared to cured/endemic as well as healthy controls.
MA and SA fractions and sub-fractions of amastigotes
induced significant lymphoproliferative and NO
responses in cured hamsters
In the previous experiment, the cellular responses of MAF2,
MAF3 and SAF2 fractions assessed in human samples were
observed to be the best among the membranous and soluble
antigens. These were further validated/assessed for their lympho-
proliferative responses in cured hamsters.
The normal control as well as cured Leishmania infected group
had shown significantly higher proliferative responses against Con
A. The SI values were 49.8764.95 and 52.6865.14 respectively
(P,0.001). On the other hand, comparatively lower mitogenic (SI-
26.8663.77) responses were observed in the cells from L. donovani
infected group (Fig. 7). Among the fractions, the most significant
lymphoproliferative responses in cured hamsters was observed
against SAF2 (24.1262.9, P,0.001) followed by SAF3
(16.6761.53, P,0.001) and nearly equally potent response was
observed in MAF2 (21.2663.055) and MAF3 (22.2163.33)
fractions. Lymphoproliferative responses against other fractions
were negligible. The LTT responses of the positive control SA and
MA were also significantly higher to the tune of 18.4661.46
(P,0.001) and 19.6661.86 respectively which was almost parallel
to its fractions.
Similar to LTT response, NO production in peritoneal
macrophages of cured hamsters and J774A.1 macrophage cell lines
was studied after 24 h of incubation in response to fractions MAF1-
MAF5, SAF1-SAF5 and positive controls (MA, SA). For compar-
ison, NO production in LPS (mitogen) stimulated and unstimulated
cells served as positive and negative controls respectively. Among
membrane fractions, MAF2 and MAF3 sub-fractions stimulated
highest level of NO production in peritoneal macrophages of
hamsters (30.5863.10 mM; 28.6362.31 mM) and J774A.1
(28.6961.514 mM; 29.0861.79 mM) cell line (Fig. 8.). However,
there was almost negligible NO production against other sub-
fractions in both the cell lines. In case of soluble sub-fractions, SAF2
stimulated highest production of NO in peritoneal macrophages of
hamsters (29.4064.69 mM) and J774A.1 (26.2962.61 mM) cell line.
It was followed by sub-fraction SAF3 with values being 17.8662.13
and 17.4561.66 in hamsters and J774.A1 cell lines respectively.
However, there was almost negligible NO production against other
sub-fractions in both the cell lines (data not shown) (Fig. 8).
Discussion
Studies on the identification of novel vaccine and drug targets
from amastigote stage of Leishmania spp are limited. This may be
perhaps due to inadequate methods to isolate the intracellular
form from host cell material. In this study, we used the classical
method by Chang et al [21] to purify amastigotes and confirmed
the purity of amastigotes microscopically using antibody raised
against PPG [29]. Western blot analysis done with the antibodies
specific for promastigote (LPG) and amastigote (A2) was to prove
that the protein lysate used for the experiments in this study was of
amastigotes. With these purified amastigotes, separated into
membrane as well as soluble fractions, in vitro immunological
studies were carried out which revealed that two fractions in the
range of 97 to 68 kDa and 68 to 43 kDa have remarkable
immunostimulatory potential.
Various approaches have been undertaken in order to identify
the most relevant molecules as vaccine candidates against
Leishmaniasis and one such approach consists of recognition of
defined antigens by PBMCs or sera from patients or animals
recovered from Leishmania infections [13,32]. Few studies have
been carried out to systematically evaluate biochemically-purified
proteins and whole parasite lysate as immunoprotective agents for
Leishmania sp [33,34,35,36,37,38], most of which are restricted to
promastigotes. It is therefore imperative to investigate the
development of human T-cell responses to different L.donovani
amastigote antigens which are of more importance being the
Immunogenecity of Splenic LD Amastigote Proteins
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pathogenic form of disease [39,40]. One of the very few studies
conducted using ‘‘axenic’’ amastigotes , identified three molecules
(P-2/A-2, P-4 and P-8) expressing preferentially in the amastigote
stage and further explored for immunization studies in BALB/c
mice [41]. The finding that two of the three molecules provided
significant protection against Leishmania infection was encouraging
and strongly supported the view that, in general, antigens
expressed by the amastigote stage are the potential source of
vaccine candidates. This instigated us to identify immunostimu-
latory antigens in amastigotes isolated from heavily infected spleen
of hamsters.
We fractionated amastigote antigen into membrane and soluble
fractions as it is well-known that both contain potential
immunogenic molecules. The membrane antigens are the first to
interact with the vertebrate host’s cells during the invasion strategy
of the Leishmania parasite. Therefore, the molecules present on the
cell surface are of paramount importance for designing the
vaccines as these could check the multiplication of parasite by
inactivating the parasitic invasion tools and also by triggering the
cell mediated immune response [42,43]. In addition, soluble
proteins can also be effective as vaccine candidates since these can
trigger immunological responses on recognition by T cells through
antigen presentation by MHC class I and MHC class II grooves,
regardless of their location in the parasite [44]. Further, since,
these membrane as well as soluble proteins are a mixture of
different antigenic proteins, it could stimulate different clones of B
Figure 5. Th1/Th2 cytokine levels (IFN-c, IL-12 p 40, IL-10) of PBMCs from cured VL patients (full course of treatment with
Amphotericin B) (&), endemic contacts (m) and healthy (o) individuals against membrane antigenic fractions used at a
concentration of 10 mg/ml (1 mg/well). The results are presented in the graph as for individual human sample along with horizontal bar
representing the median.
doi:10.1371/journal.pone.0030746.g005
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& T cells [45,46]. Therefore, it is essential to identify specific TH1
stimulatory protective proteins from the Leishmania amastigote
antigens through activity guided fractionation.
Using conventional screening approach, we have identified
soluble fractions SAF2 followed by SAF3, which could stimulate
the lymphocytes in vitro by inducing the release of very high
amount of IFN-c and IL-12p40, the molecules involved in cell-
mediated protective immunity [47,48,49,50], in cured patients/
endemic contacts. Moreover, equally efficient immuno-protective
response was obtained in membranous ones i.e. MAF2 and
Figure 6. Th1/Th2 cytokine levels (IFN-c, IL-12 p 40, IL-10) of PBMCs from cured VL patients (full course of treatment with
Amphotericin B) (&), endemic (m) and healthy (o) individuals against soluble antigenic fractions used at a concentration of 10 mg/
ml (1 mg/well). The results are presented in the graph as for individual human sample along with horizontal bar representing the median.
doi:10.1371/journal.pone.0030746.g006
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MAF3. However, rest of the antigenic sub-fractions did not induce
proliferation or IFN-c/IL12p40 production in healthy as well as in
VL infected control subjects evaluated. On the other hand, the
level of IL-10 against SAF2 and MAF2 as well as MAF3 followed
by SAF3 was found suppressed in cured patients as well as in
endemic contacts. These findings indicate a clear-cut and specific
up-regulation of Th1 stimulatory responses with parallel down-
regulation of Th2 stimulatory responses in cured patients.
Noticeably in endemic controls the overall proliferative/cytokine
responses of T-cells were not as high as observed in recovered
ones. The presence of positive immune response in 60% of the
endemic controls in this study supported the observation of
Tripathi et al [51] that frequency of sub-clinical infections in an
endemic area like Bihar is high which has also been reported in
other areas of the world [52,53]. The heterogeneity in the pattern
of responses in recovered cases may have been attributed to the
extent and duration of infection or the genetic restriction of the
host anti-leishmanial T cells [54].
The immunogenicity data of these fractions and subfractions
obtained with human PBMCs was further translated in hamster
model. The reason behind taking hamster as experimental model
was the fact that infection in golden hamsters [55] mimics several
aspects of human disease, such as hepatosplenomegaly, pancyto-
penia, progressive cachexia, hypergammaglobulinemia, and sup-
pression of T-cell proliferative response to parasite antigens [56].
Hence, it would be relevant to corroborate the observations on
immunological responses of human lymphocytes with the animal
model being used further for vaccination studies. In tune with the
human data, almost all the cured animals too exhibited
conspicuous stimulatory responses to the fractions SAF2, MAF2,
MAF3 followed by SAF3 as evident by T cell proliferation.
Recovery from Leishmania infection relies on induction of the Th1
response [57] with production of IFN-c and IL-12 and enhanced
expression of nitric oxide synthase [58]. Besides leishmanicidal
activity, NO is also known to regulate immunological pathways
including endogenous IL-12 secretion [59]. Therefore, in the
absence of cytokine reagents for hamsters, nitric oxide assay was
used to indirectly estimate the IFN-c response, as NO is up-
regulated by IFN-c. The effect of the fractions on NO production
was also validated in J774A-1 cell line.
Inference drawn from the overall immunogenic responses
strongly suggests that the sub-fractions SAF2, MAF2 and MAF3
are the most immunopotents. Further, the cellular responses of
SAF3 sub-fraction, though less as compared to other fractions, was
remarkable. This suggest that these sub-fractions have some potent
molecules that might have epitopes readily recognized by T-cells
from both treated/cured as well as endemic individuals presum-
ably sensitized with L. donovani. Besides, the cellular responses to
potent fractions of both promastigotes [13,32] and amastigotes of
L. donovani were similar in endemic controls and in cured patients
of VL as well as in hamsters, which would provide a strong basis
for the hypothesis that the observations of vaccination studies of
hamsters could be translated into humans.
To surmise, this finding leads to the first step of antigen selection
in experimental models as well as in human being, in order to
evaluate ability to induce protection against leishmanial infection.
These in vitro findings need essential validation through vaccination
studies in in vivo models to move ahead. Further, the results have
Figure 7. Lymphoproliferative response of mononuclear cells
of lymph nodes from normal, L. donovani infected as well as
cured (with Miltefosine at 40 mg/kgx5 days) hamsters in
response against MA (A) and SA (B).
doi:10.1371/journal.pone.0030746.g007
Figure 8. Nitric oxide production (mM) by peritoneal macro-
phages of hamsters (n=9) and J774 cell lines in response to
MA (A) and SA (B) at 10 mg/ml after 24 h stimulation. The
absorbance of the reaction product was measured at 540 nm using
Griess reagent.
doi:10.1371/journal.pone.0030746.g008
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also emphasized the necessity to dissect the potent fractions
through proteomics to identify the specific proteins which are
immunostimulatory.
Materials and Methods
Animal
Laboratory bred male golden hamsters (Mesocricetus auratus, 45–
50 g) were employed for experimental work and maintained in
plastic cages (38627613 cms) with standard rodent pellets diet
(Lipton India Ltd.) and water ad libitum.
Parasites
The L. donovani (strain 2001) were grown in RPMI-1640
medium (in vitro) supplemented with 10% heat-inactivated foetal
bovine serum (Sigma, USA) at 25uC as described previously
[13,20]. Leishmania parasites have also been maintained in
hamsters (in vivo) through serial passage, i.e., from amastigote to
amastigote [13].
Isolation of Amastigotes
Splenic amastigotes were isolated as per method described by
Chang [21]. Briefly, the hamsters with well established
infection (45–60 day old) were sacrificed, spleen removed
aseptically in sterile Phosphate Buffer Saline (PBS) and cut into
small pieces. The Splenic tissue was homogenized gently with
the help of motor driven tissue homogenizer, consisting of glass
mortar and Teflon pestle at 4uC. The suspension was
centrifuged at 9006g for 10 min at 4uC, allowing the tissue
debris to settle down. The supernatant was centrifuged at
30006g for 20 min. at 4uC. The supernatant was discarded and
the sediment containing amastigotes was re-suspended in RBC
lysis solution to lyse the RBC. The suspension was centrifuged
again at 30006g at 4uC and pellet so obtained was dissolved in
PBS-EDTA (2 mM), and then centrifuged at 30006g at 4uC for
10 min. The amastigotes pellet so obtained was purified using
percoll (Sigma, USA) density gradient centrifugation as
described previously [21].
Immunofluorescence using confocal microscopy
The purified amastigote suspension containing 105 cells in
400 ml were adhered on poly-L-lysine coated cover slips and were
fixed for 20 min in 4% paraformaldehyde in PBS (pH 7.2). Cells
were washed 3 times with 200 ml of PBS-glycine (0.5%),further
blocked with 100 ml of 1% BSA (Bovine Serum Albumin) for
30 minutes at room temperature and incubated with a 100 ml of
rabbit polyclonal antiserum raised against dephosphorylated
proteophosphoglycan (PPG) (1:200 diluted) for 30 minutes at
room temperature . The cells then were again washed 6 times with
100 ml of 1% BSA and incubated with 100 ml of fluorescein
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG antibodies
(Bangalore Genei, India)(1:500 dilution) for 1 hour at 4uC in dark
humid chamber.
Western Blot analysis of pure amastigotes
The whole cell lysate (WCL) of splenic amastigotes as well as
promastigotes of clinical isolate of L. donovani was prepared by
boiling 107 cells in 100 ml of 26sample buffer (100 mM Tris-HCl,
200 mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol)
for 10 min in water bath and chilled on ice. Then the samples
were centrifuged at 80006g for 10 minutes and 25 ml (300 mg/
lane) of supernatant was separated on two sets of SDS-PAGE
containing 6% stacking and 10% separating gels. One set of gel
was stained with Coomassie blue and the other was used for
transferring proteins to nitrocellulose membrane using Hoefer
Semi-dry transfer assembly at 0.8 mA/cm2 of NC membrane
[22,23]. Successful transfer of the proteins was verified by the
transfer of the pre-stained molecular weight standards (Fermen-
tas, USA). Following overnight blocking of non-specific binding
sites in 5% skimmed milk, NC membrane was probed with
different antibodies viz. A2 (Medimabs, Montreal, Canada), LPG
(GenWay Biotech, San Diego, CA) followed by incubation with
horseradish peroxidase (HRP) conjugated goat anti-rabbit
antibodies (Bangalore Genei, India) (1/5000 dilution). Grp78
protein (from Dr Emanuela Handman, Australia) was used as
loading control. After washing with PBS-T (0.05% Tween-20),
the protein bands detection was performed in dark, using the
Amersham ECL kit of enhanced chemiluminescence (Amersham
Biosciences, Singapore). Briefly, the NC membrane was incu-
bated for 5 minutes with detection solutions (A and B at 40:1
ratio) and then the membrane was wrapped up with SaranWrap
and was placed in an x-ray film cassette. A sheet of
autoradiography film (Amersham Biosciences, Singapore) was
then placed on the top of the membrane and cassette was closed
and the membrane was exposed for 10 minutes. Finally, the
membrane was developed by developer and was fixed by the
fixer.
Fractionation of L. donovani amastigote proteins
Soluble protein (SA). Soluble L. donovani amastigote antigen
(SA) was prepared as per method described by Scott et al., [24]
and modified by Choudhry et al., [25]. Briefly, isolated
amastigotes were suspended in PBS and sonicated (Soniprep-
150) for two periods of 1.5 min each in ice, (separated by an
interval of 3 min) at medium amplitude. The sonicated sample
was rapidly frozen and thawed 4 times using liquid nitrogen and
left at 4uC for one hour for complete extraction of soluble
antigen. The suspension was centrifuged at 4,000 g for 20 min at
4uC. The supernatant so obtained was finally ultra centrifuged at
40,000 g for 30 min. After assessing protein contents (Bradford
method), the antigen was distributed in small aliquots and stored
at 270uC.
Membrane protein (MA). Membrane antigen (MA) was
prepared using the method of Molloy et al. [26]. Briefly,
amastigotes were disintegrated using freeze-thawing in liquid
nitrogen and then lysed by ultrasonication in TNE buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) with Protease
inhibitor cocktail (Sigma, USA). The lysate was then incubated
with 0.1 M sodium carbonate for 1 h at 4uC. Finally, MA was
collected by ultracentrifugation in a Beckman ultracentrifuge (CA,
USA) at 1200006g for 1 h at 4uC. Such a pre-fractionation of the
proteins reduces the complexity of 2-D maps by removing most
non-membrane proteins [27].
Sub-fractionation of SA and MA proteins in to five sub-
fractions (MAF1-MAF5, SAF1-SAF5) by continuous-
elution gel electrophoresis
SA as well as MA were prepared and resolved by 12% SDS-
PAGE as described earlier. Resolved fractions of interest were
identified with the help of pre-stained molecular weight markers
run simultaneously and cut using sharp and clean scalpel. The
bands were designated as F1 to F5. Proteins from gel strips were
electro eluted (Electroeluter, Millipore, India), concentrated
(Centricon of 3 10 and 30 kDa cut off; Millipore, India), and
content estimated (Bradford method) . The molecular weight of
the proteins in fractions was confirmed in 1D SDS-PAGE as above
and then stored in aliquots at 220uC till use.
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Donors and isolation of mononuclear cells
A brief account of clinical samples has been given in Table 1.
The study groups of clinical blood samples taken were as follows:
(i) Ten treated/cured patients from Kala-azar Medical
Research Centre, Muzzafarpur (hyper-endemic area of
Bihar) who had recovered from VL. Seven were males and
three females, their age ranging from 2 to 32 years.
Diagnosis was established in all cases by demonstration of
parasites in splenic aspirates. All patients had received full
course of Amphotericin B (Fungizone). Samples were
collected two months to one year after completion of
treatment. Their splenic aspirates were negative for
parasites at the time of study
(ii) Nine endemic household contacts, i.e. 5 males and 4
females, their age ranging from 20–58 years, were taken
from Kala-azar Research centre. They neither showed any
clinical symptoms nor received any anti leishmanial
treatment.
(iii) Six infected patients viz. 2 males and 4 females belonging
to Leishmania endemic area were taken from the above
stated centre; their age ranging from 5 to 20 years, showing
clinical symptoms and presence of parasites in their splenic
aspirates.
(iv) Seven normal healthy donors were taken from non
endemic areas. There were 6 males and one female, their
age ranging from 25 to 30 years. They served as negative
control as they never had any exposure to Leishmania
infection and also have never travelled to Leishmania
endemic area.
Approximately 10 ml of heparinized venous blood was collected
from all the study subjects. Blood was mixed with equal amount of
PBS (1.5 M, pH 7.4) and then 10 ml of diluted blood was layered
on 5 ml (i.e. 2: 1 ratio) Ficoll Hypaque (Histopaque 1077- Sigma,
USA). PBMCs were then isolated by centrifugation at 10006g at
room temperature for 30 min. The isolated PBMCs were washed
three times with incomplete RPMI medium at 10006g for 15 min,
9006g for 12 min and 9006g for 10 min. A final suspension of
16106 cells/ml was made with complete RPMI medium [HEPES-
buffered RPMI-1640 supplemented with streptomycin (100 mg/
ml), Penicillin (100 U/ml), L-glutamine (2 mM), b-mercaptoeth-
anol (561025 M) and 10% heat inactivated fetal bovine serum]
after determining cell viability by trypan blue staining method
(Tripathi et al., 2006).
Treatment of L. donovani infected hamsters with
antileishmanial drug and isolation of mononuclear cells
Approximately 30 hamsters, infected with 107 amastigotes
intracardially, were assessed for parasitic burden one month later
by splenic biopsy through a small incision in the upper left quarter
of the abdomen and a small piece of splenic tissue was cut and dab
smears were made on slides. The incised portion was stitched with
nylon suturing thread. Following biopsy, an adequate amount of
antibiotic powder (Neosporin, Burroughs Wellcome Ltd., India)
was applied on the stitched portion and finally sealed with tincture
of benzoin. In addition, neosporin sulphate (100 mg/kg of body
weight) was also given orally the day before and the day after the
biopsy for healing. The smears were fixed in methanol and stained
with Giemsa stain and the number of amastigotes/1000 cell nuclei
was counted. The animals harbouring .20–25 amastigotes/100
macrophage cell nuclei were then treated with Miltefosine-an
antileishmanial drug (Zentaris, Germany) at 40 mg/kg body-
weight daily for 5 days. The animals were reassessed for complete
cure by splenic biopsy performed on day 30 post treatment.
Lymph nodes (inguinal and mesenteric) from individual infected,
treated/cured as well as normal hamsters were removed
aseptically and placed in a petridish containing incomplete
RPMI (iRPMI) medium. After 3–4 washing in iRPMI medium,
lymph nodes were teased with sterile needles and then crushed
with sterile pestle in petridishes. The suspensions so obtained
were transferred into the sterile centrifuge tubes and centrifuged
at 10006g for 5 minutes to settle down the debris if any.
Supernatants were re-centrifuged in another tube at 15006g for
10 min. to spin down the lymphocytes. The cells were washed
thrice with iRPMI and a final suspension of 16106cells/ml was
made in cRPMI medium.
Lymphoproliferative responses in cured/endemic
patients and cured hamsters against five fractions
Lymphocyte proliferation assay was performed to evaluate cell-
mediated immune response of cured/endemic patients and cured
hamsters to leishmanial antigens. Suspension of PBMCs (16106/
ml) of both patients and hamsters was cultured in 96 well flat
bottom tissue culture plates (Nunc, Denmark). About 100 ml of
mitogens - PHA (10 mg/ml Sigma, USA), Con A (10 mg/ml,
Sigma, USA) as well as antigens i.e. subfractions SAF1 to SAF5
and MAF1 to MAF5 (10 mg/ml each), predetermined concentra-
tion, were added to the wells in triplicate. For comparison, SA and
MA (10 mg/ml each) were employed as positive controls. Wells
without stimulants served as negative control. Cultures were
incubated at 37uC in a CO2 incubator with 5% CO2 for 3 days in
the case of the mitogens, and for 5 days in the case of the antigens.
Eighteen hours prior to termination of culture, 0.5 mCi of [3H]-
Thymidine (BARC, India) was added to each well .They were
then harvested on glass fibre mats (Whatman) and counted in a
liquid scintillation counter. Results were expressed as stimulation
index (SI) which was calculated as mean counts per minute (cpm)
of stimulated culture/mean cpm of unstimulated control. SI values
of unstimulated control group were compared with the values of
stimulated (with antigen) groups and SI of more than 2.5 was
considered as positive response.
Table 1. Size and type of clinical samples taken for the study.
Healthy controls
Infected
controls Endemic controls Recovered/cured patients
Number 7 6 9 10
Age (Yrs) 25–30 5–20 20–58 2–32
Male/Female 6/1 2/4 5/4 7/3
Treatment Nil Nil Nil Amphotericin
doi:10.1371/journal.pone.0030746.t001
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SI~
Average of mean counts per min in stimulated culture
Average of mean counts per min in unstimulated culture
Estimation of level of cytokines (IFN-c/IL-12p40/IL-10) in
lymphocytes of cured/endemic patients against five
fractions
As mentioned above, culture of PBMCs from human patients
was set up in 96 well culture plates and 16106 cells/ml were
dispensed and antigenic fractions were added at a concentration of
10 mg/ml in triplicate wells with a final concentration of 1 mg/
well. IFN-c IL-12p40 and IL-10 levels in the 24 hrs antigen
stimulated supernatants were determined by enzyme-linked
immunosorbent assay kit (OptEIA set, Pharmingen). The results
were expressed as picograms of cytokine/ml, based on the
standard curve of the standards of respective cytokine provided
in the kit. The lower detection limits for various cytokines were as
follows: 5.1 pg/ml for IFN-c, 30.8 pg/ml for IL-12p40 and
6.9 pg/ml for IL-10.
Assessment of NO production in macrophages against
five sub-fractions
The presence of NO was assessed using Griess reagent in the
culture supernatants of naı¨ve hamster peritoneal macrophages as
well as macrophage cell line J774.1 after the exposure with
supernatant of stimulated lymphocyte’s cultures and LPS (10 mg/
ml Sigma, USA) was used as mitogen (Sigma) [28]. Isolated
peritoneal macrophages were suspended in culture medium and
plated at 106 cells/well and exposed to the supernatants of above
described 5-day-old antigen stimulated lymphocyte’s cultures from
all the study groups. The supernatants (100 ml) collected from
macrophage cultures 24 h after incubation was mixed with an
equal volume of Griess reagent (Sigma, USA) and left for 10 min
at room temperature. The absorbance of the reaction was
measured at 540 nm in an ELISA reader.
Ethics Statement
The study and the protocol was approved by the Ethics
committee of the Kala-azar Medical Research Centre, Muzza-
farpur and CDRI and all patients provided a written consent
before enrolment to this study. Experiments on the animals
(hamsters) were performed following the approval of the protocol
and the guidelines of Institutional Animal Ethics Committee
(IAEC) of the CDRI. The approval reference number is 126/08/
Para/IAEC dated 27.08.2008
Statistical analysis
The results (pooled data of three experiments) were analyzed by
one-way ANOVA followed by Tukey’s post test where appropri-
ate. All of the analyses were done using GraphPad Prism (version
3.03) software. The upper level of significance was chosen as
P,0.001.
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